article thumbnail

New male contraceptive does not involve hormones

Medical Xpress

Instead of using hormones to disrupt sperm production, the new technique involves placing a hydrogel called ADAM into the vas deferens to prevent sperm from making its way to the urethra.

Hormones 143
article thumbnail

Pfizer’s Ngenla Approved as Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (GHD)

XTalks

Pfizer has been going strong on the approval front, having secured its fifth US Food and Drug Administration (FDA) approval in the past five weeks, with the most recent being for the company’s once-weekly human growth hormone analog Ngenla (somatrogon-ghla).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Pharmaceutical Technology

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered orally.

Hormones 100
article thumbnail

Alzheimer’s Is More Common in Women, And This May Help Explain Why

AuroBlog - Aurous Healthcare Clinical Trials blog

Now two new studies raise the possibility of complex interactions between hormones and […] In the US, roughly two out of every three people with Alzheimer’s is a woman, a statistic that could be partially explained by the fact women typically live longer than men. Yet researchers have suspected there could be more to the story.

Hormones 217
article thumbnail

Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com

BioTech 365

Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Hormone Deficiency – Global Clinical Trials Review, H1, 2021” clinical trials has (..)

article thumbnail

New hormonal agent may slow progression of early-stage prostate cancer during active surveillance

Medical Xpress

For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in the Journal of Urology.

article thumbnail

Adding capivasertib to fulvestrant improves progression-free survival of hormone receptor-positive breast cancer

Medical Xpress

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented (..)